AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

ATTORNEYS AT LAW

One Commerce Square - 2005 Market Street - Suite 2200 - Philadelphia, PA 19103 TELEPHONE: (215) 965-1200 - FACSIMILE: (215) 965-1210

E-MAIL: kdoyle@akingump.com

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below

Angela Kryszczak

Type or print name of person signing certification

FACSIMILE COVER SHEET

Examiner: S. Ungar

FAX No.: 703-308-4426

Group Art Unit: 1644

Date: November 30, 2000

From: Kathryn Doyle, Ph.D., J.D.

FAX Operator: Angela

Re:

Application No. 09/487,979 of Skurkovich et al., for "Treatment of Autoimmune

Diseases, Including AIDS.

Title of Paper sent via Facsimile: Second Preliminary Amendment

Time: 10:34

Akin, Gump File No: 200011.0015/1U9

Page 1 of $\frac{\mathcal{J}}{\mathcal{J}}$ pages

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CONTACT ANGELA AT 215-965-1301

Attached herewith for filing is a Second Preliminary Amendment in the above-identified application.

THIS FACSIMILE MESSAGE IS CONFIDENTIAL AND MAY CONTAIN ATTORNEY PRIVILEGED INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR COMPANY NAMED ABOVE.

PATENT BOX NON FEE AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

Skurkovich et al.

Skurkovich et at.

Appln. No:

09/487,979

Filed:

January 20, 2000

For:

TREATMENT OF AUTOIMMUNE

DISEASES, INCLUDING AIDS

Group Art Unit

1644

Examiner:

S. Ungar

Attorney Docket

: No. 0011-1U9

(200011.0015)

SECOND PRELIMINARY AMENDMENT

In the Preliminary Amendment filed on January 20, 2000, Applicants requested that claims 33-58 be canceled and that new claims 59-67 be added. This was error. Applicants hereby request that the following amendments to the claims be entered.

In the Claims:

Please cancel claims 1-32, and 59-67 (as presented in the Preliminary Amendment filed on January 20, 2000).

Please add claims 33-41 as follows:

comprising administering to said patient an effective amount of a plurality of at least two autoimmune inhibitors selected from the group consisting of an antibody to alpha interferon, an antibody to alpha interferon receptor, alpha interferon receptor, an antibody to gamma interferon, an antibody to gamma interferon receptor, gamma interferon receptor, an antibody to tumor necrosis factor, an antibody to tumor necrosis factor receptor, tumor necrosis factor receptor, an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor.

The method of claim 33, wherein said plurality of autoimmune inhibitors comprises (a) at least one autoimmune inhibitor selected from the group consisting of an

PH H